Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company shared top-line final data from its phase I study of Cantrixil (TRX-E-002-1) … Continue reading Top-line final data from CD-enabled Cantrixil Phase I study confirms prior positive efficacy and safety signals